Company intelligence / Profile preview

Humanigen

Burlingame, California, United Statesir.humanigen.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Humanigen develops proprietary monoclonal antibodies using its Humaneered® technology. Its lead candidate, lenzilumab, targets GM-CSF and has been evaluated in late-stage clinical trials for COVID‑19 and hematologic cancers. The company also develops ifabotuzumab targeting EphA3 for solid tumors. Lenzilumab showed promise in reducing cytokine storm in severe COVID‑19 but did not meet all endpoints in pivotal studies. Programs continue for rare leukemias with orphan drug designations sought.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Recombinant antibodies
Industry: Biotech

Drug pipeline

2 assets

lenzilumab

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Humanigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Humanigen.

Explore the full profile